BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting

BrainXell Showcases Pioneering iPSC Research at SfN 2025

On November 15, 2025, BrainXell, Inc. made headlines by announcing their participation in the 2025 Society for Neuroscience (SfN) Annual Meeting, which takes place in San Diego. The company will present groundbreaking data in poster sessions that highlight the potential of their innovative research in human induced pluripotent stem cell (iPSC) technology, especially concerning neurodegenerative diseases such as Parkinson's Disease.

The upcoming posters will underline three main themes: scalable cell-based assays, advanced disease modeling, and next-generation cell therapies. Dr. Su-Chun Zhang, a leading figure in stem cell neuroscience and the Founder & Advising Chief Scientific Officer (CSO) of BrainXell, emphasized the company’s commitment to advancing biomedical discoveries. “We are at the forefront of the biotechnology revolution, pioneering cellular platforms that not only aid in scientific discovery but also in clinical translation into practical therapies,” stated Dr. Zhang.

Highlights of BXT-110 for Parkinson's Disease

Among the standout presentations will be data showcasing BXT-110, an autologous iPSC-derived midbrain dopaminergic progenitor (mDAP) therapy developed for treating Parkinson's disease. Preliminary findings demonstrate remarkable results, with over 75% expression of FOXA2+/OTX2+ and more than 60% of neurons expressing TH+ in vitro. Moreover, graft survival rates exceeded 60% in in vivo conditions. These promising results culminate in functional efficacy noted in rodent models, showing significant behavioral recovery within just 12 weeks post-transplantation of BXT-110. This reinforces BXT-110's position as a viable contender for disease-modifying therapies.

The poster presentation for BXT-110 is scheduled for November 19, 2025, at 1:00 PM, located at Booth #438.01, where attendees can gain a detailed understanding of the innovations surrounding this groundbreaking treatment.

Innovations in Neurovascular Modeling

In addition to their work on BXT-110, BrainXell will introduce a revolutionary 3D neurovascular microfluidic model of the human blood-brain barrier. This tri-culture system ingeniously unites endothelial cells, astrocytes, and pericytes to accurately replicate the barrier's integrity and permeability. This model serves as a crucial quantitative platform for studying CNS drug transport and safety. The corresponding poster presentation is set for today, November 15, at 1:00 PM, at Booth #369.09.

Accelerated Differentiation Protocol for Oligodendrocyte Progenitors

Another exciting aspect of BrainXell's presentation includes a new protocol for rapid differentiation of hiPSC-derived oligodendrocyte progenitor cells. This process results in more than 95% purity of O4⁺ expressing cells within just 30 days, which also show expression of key myelin markers such as MBP, MOG, and PLP1. When integrated into 3D co-cultures, these cells demonstrate enhanced myelination, providing researchers with advanced tools for studying remyelination. Attendees can catch this presentation on November 19 at 8:00 AM at Booth #369.23.

Development of Multilineage 3D Neural Spheroids

Lastly, BrainXell has engineered multilineage 3D neural spheroids that integrate neurons, astrocytes, and microglia. This innovative model showcases coherent network activity, synaptic signaling, and neuroinflammatory responses, bridging the gap between in vitro assays and in vivo biology. The related poster will be presented on November 19 at 8:00 AM, at Booth #401.06.

The SfN meeting provides an unparalleled opportunity for BrainXell to showcase its cutting-edge research innovations and clinical applications. Attendees are encouraged to visit Booth #728 to engage directly with BrainXell's scientific team and explore the future of regenerative medicine and neural therapy.

About BrainXell

Founded by renowned stem cell scientist Dr. Su-Chun Zhang, BrainXell, Inc., based in Madison, WI, and its therapeutics division in San Diego, CA, are committed to advancing iPSC-based solutions for discovery and regenerative medicine. Through scientific excellence and innovative manufacturing, BrainXell aims to accelerate cures for CNS diseases. For further information, please explore www.brainxell.com.